MedTrace Logo

Effects of Vigiis 101-LAB on a Healthy Populations' Gut Microflora, Peristalsis, Immunity, and Anti-oxidative Capacity

NCT04046432 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2019-08-07

No results posted yet for this study

Summary

Vigiis 101-LAB capsules I and II are produced from the fermentation of Lactobacillus paracasei subsp. paracasei NTU 101. Investigators have examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day, respectively) on gut microflora in clinical trial 1, and on peristalsis, related immunity, and anti-oxidative capacity in clinical trial 2, during a 4-week randomized, double-blind, placebo-controlled, adaptive-design study.

Conditions

  • Gastrointestinal Microbiome

Interventions

DIETARY_SUPPLEMENT

Vigiis 101-LAB

examined the effects of the Vigiis 101-LAB capsules I or II (5 or 10 billion CFU/day)

DIETARY_SUPPLEMENT

Placebo

Maltodextrin was used as a placebo.

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Chung Shan Medical University

    collaborator OTHER

  • SunWay Biotech Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Tsong Ming Lu, MD

  • Jyh Ming Liou, MD.,PHD

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-27
Primary Completion
2017-12-22
Completion
2018-03-20

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04046432 on ClinicalTrials.gov